Mr. Elizabeth Ann Eckhard, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 51 Colony Hill Ct, Halethorpe, MD 21227 Phone: 410-737-0114 |
Ms. Kimaya Kishor Parkar Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3320 Benson Ave, St. Elizabeth's Rehabilitation And Nursing Home, Halethorpe, MD 21227 Phone: 410-644-7100 |
Teresa Smith, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3004 New York Ave, Halethorpe, MD 21227 Phone: 443-722-3891 |
News Archive
Further helping to secure public health, a second round of revised quality standards for the widely used blood thinner heparin became effective today, the U.S. Pharmacopeial (USP) Convention announced. Working closely with the Food and Drug Administration (FDA), the pharmaceutical industry, and other regulatory and scientific bodies, USP started initial revisions in 2008 after adverse reactions and deaths resulted from heparin intentionally adulterated with over-sulfated chondroitin sulfate (OSCS).
Something rotten never smelled so sweet. This is what members of a team of scientists at Cold Spring Harbor Laboratory (CSHL) are telling one another as they discuss a new finding they did not expect to make. They have discovered that hydrogen sulfide (H2S) - the flammable, highly toxic gas that we usually associate with the smell of rotten eggs in landfills and sewers - plays an important role in the regulation of a signaling pathway implicated in biological malfunctions linked to Alzheimer's and Parkinson's diseases, among others.
Certain tumors of the pituitary gland are associated with glaucomatous abnormalities of the optic nerve head, such as enlarged beta zone, an international research team reports.
Labeling foods and beverages as less-healthy and taxing them motivates people to make healthier choices, finds a recent study in the American Journal of Preventive Medicine.
ConjuChem Biotechnologies Inc. announced today that the U.S. Patent & Trademark Office (USPTO) has issued a Right of Appeal Notice (Final Office Action) in the inter partes reexamination of Patent No. 6,924,264. The patent, entitled "Modified Exendins and Exendin Agonists," was issued in August 2005 and is assigned to Amylin Pharmaceuticals, Inc. The Action once again rejected all the subject claims for obviousness and/or lack of novelty. The inter partes reexamination in the USPTO does not involve any of ConjuChem's patents.
› Verified 5 days ago